The topic of this article may not meet Wikipedia's general notability guideline. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources:  "Avecia" –  news · newspapers · books · scholar · JSTOR (September 2023) ( Learn how and when to remove this message)

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources:  "Avecia" –  news · newspapers · books · scholar · JSTOR (September 2023) ( Learn how and when to remove this message)

Avecia, a part of Nitto Denko Inc., ^[1] is a private biotechnology company focused on the development and manufacture of novel medicines using biotechnology techniques. Avecia operates as a contract manufacturing organization (CMO), specializing in oligonucleotide production.^{[ citation needed]}

Avecia has two US FDA-audited facilities, one near Boston, MA, and the second in Cincinnati, OH. The combined capacity of these two sites allows Avecia to handle oligonucleotide programs from the pre-clinical through commercial stages. In 2016 Avecia acquired the assets of Irvine Pharmaceutical Services and Avrio Biopharmaceuticals.^{[ citation needed]}

References

External links

• Avecia.com